117 related articles for article (PubMed ID: 9397201)
1. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients.
Murphy GP; Maguire RT; Rogers B; Partin AW; Nelp WB; Troychak MJ; Ragde H; Kenny GM; Barren RJ; Bowes VA; Gregorakis AK; Holmes EH; Boynton AL
Prostate; 1997 Dec; 33(4):281-5. PubMed ID: 9397201
[TBL] [Abstract][Full Text] [Related]
2. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
[TBL] [Abstract][Full Text] [Related]
3. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients.
Elgamal AA; Troychak MJ; Murphy GP
Prostate; 1998 Dec; 37(4):261-9. PubMed ID: 9831223
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans.
Murphy GP; Snow PB; Brandt J; Elgamal A; Brawer MK
Prostate; 2000 Feb; 42(2):145-9. PubMed ID: 10617872
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific membrane antigen: current and future utility.
Gregorakis AK; Holmes EH; Murphy GP
Semin Urol Oncol; 1998 Feb; 16(1):2-12. PubMed ID: 9508077
[TBL] [Abstract][Full Text] [Related]
7. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.
Murphy G; Ragde H; Kenny G; Barren R; Erickson S; Tjoa B; Boynton A; Holmes E; Gilbaugh J; Douglas T
Anticancer Res; 1995; 15(4):1473-9. PubMed ID: 7544569
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
10. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
[TBL] [Abstract][Full Text] [Related]
11. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
12. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy.
Proaño JM; Sodee DB; Resnick MI; Einstein DB
J Urol; 2006 May; 175(5):1668-72. PubMed ID: 16600726
[TBL] [Abstract][Full Text] [Related]
13. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
Beckett ML; Cazares LH; Vlahou A; Schellhammer PF; Wright GL
Clin Cancer Res; 1999 Dec; 5(12):4034-40. PubMed ID: 10632336
[TBL] [Abstract][Full Text] [Related]
15. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men.
Douglas TH; Connelly RR; McLeod DG; Erickson SJ; Barren R; Murphy GP
J Surg Oncol; 1995 Aug; 59(4):246-50. PubMed ID: 7543173
[TBL] [Abstract][Full Text] [Related]
16. PSA-PSMA profiles and their impact on sera PSA levels and angiogenic activity in hyperplasia and human prostate cancer.
Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
Pathol Biol (Paris); 2014 Jun; 62(3):129-36. PubMed ID: 24745345
[TBL] [Abstract][Full Text] [Related]
17. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.
Wilkinson S; Chodak G
J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753
[TBL] [Abstract][Full Text] [Related]
18. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
[TBL] [Abstract][Full Text] [Related]
19. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
